InMed Pharmaceuticals (NASDAQ:INM), a leader in pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogues, has unveiled a new program for combating neurodegenerative diseases (“INM-900 series”). The program will focus on studying the effects of cannabinoid analogues in neurodegenerative diseases such as Alzheimer’s disease, Huntington’s disease and Parkinson’s disease. Prior to this announcement, InMed had identified potential cannabinoid analogs that showed promising effects, particularly in the treatment of neurodegenerative diseases; the new program will focus on two main analogues to conduct studies using live models to select the most suitable candidate for clinical studies. The company anticipates that the early readout of preclinical efficacy will be available by the second quarter of Q2 2023. Dr. Ujendra Kumar of the University of British Columbia (“UBC”) received a grant from the Council of Natural Sciences and Engineering Research Canada (“NSERC”) Alliance to lead the research, with InMed named industry partner. The collaborative project is entitled “Pharmacological characterization of phytocannabinoids and the endocannabinoid system”. “We are pleased that our efforts have led to the identification of two cannabinoid analog candidates to transition to. live studies,” Eric Hsu, PhD, senior vice president of preclinical research and development at InMed Pharmaceuticals, said in the press release. “Our team will continue this important research in neurodegenerative diseases thanks to the NSERC Alliance grant. Our early studies show promising neuroprotective effects as well as neurite outgrowth, signifying the potential for improved neuronal function that may be important in the treatment of neurodegenerative diseases. This program, in conjunction with the work we do in glaucoma, increases our focus and expands our pipeline in the area of neuroprotection. »
To view the full press release, visit https://ibn.fm/JhvKf
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a world leader in pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogues, including clinical and preclinical programs targeting the treatment of diseases with unmet medical needs. The company also has significant expertise in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, please visit www.InMedPharma.com.
NOTICE TO INVESTORS: The latest news and updates relating to INM can be found in the company’s newsroom at https://ibn.fm/INM
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full range of corporate communications solutions. As a multi-faceted financial news and content distribution company with an extensive team of journalists and writers, BMW is uniquely positioned to best serve private and public companies wishing to reach large audiences. investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 major syndication outlets across the country. By reducing the information overload in today’s market, BMW provides customers with unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS alerts from BioMedWire, text “Biotech” to 844-397-5787 (US cell phones only)
For more information, please visit https://www.BioMedWire.com
Please review the full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever posted or republished: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork
